Date post: | 19-Dec-2016 |
Category: |
Documents |
Upload: | truongminh |
View: | 232 times |
Download: | 5 times |
CURRICULUM VITAE
Elizabeth Carloss Riley M.D., FACP
James Graham Brown Cancer Center
University of Louisville
529 S. Jackson Street
Louisville, KY 40202
502-562-4370
502-562-6811 (fax)
EDUCATION
1998 B.A. Duke University, Durham, NC (English)
2002 M.D. University of Louisville, Louisville, KY
2002-2003 Intern, Internal Medicine, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston MA
2003-2005 Resident, Internal Medicine, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA
2005-2006 Fellow, Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA
2006-2007 Chief Resident, Internal Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA
2007-2009 Fellow, Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA
ACADEMIC APPOINTMENTS
2002-2006 Clinical Fellow in Medicine
Harvard Medical School
Boston, MA
2006-2007 Instructor in Medicine
Harvard Medical School
Boston, MA
2007-2009 Clinical Fellow in Medicine
Harvard Medical School
Boston, MA
2009- present Assistant Professor of Medicine
Division of Medical Oncology/Hematology
University of Louisville
Louisville, KY
2013-present Assistant Division Director
Division of Medical Oncology/Hematology
University of Louisville
Louisville, KY
2013-present Director, Breast Multidisciplinary Clinic
James Graham Brown Cancer Center
University of Louisville
Louisville, KY
Elizabeth Riley, M.D., FACP 7/25/14
Page 2 of 19
2
OTHER POSITIONS AND EMPLOYMENT
1997 ULCA School of Public Health, Los Angeles, CA
Analyzed community health indicators for Healthy People 2000.
1998 United States Senate, Washington, D.C.
Researched and prepared information relating to education and health care in Senator
Mitch McConnell’s office
2005-2006 Medical Staff
Department of Medicine
Division of Hematology/Oncology
Mount Auburn Hospital
Cambridge, MA
CERTIFICATION AND LICENSURE
2002 Massachusetts Medical License (# 220429)
2006 Diplomat, American Board of Internal Medicine (ABIM)
2009 Diplomat, ABIM, subspecialty Medical Oncology
2009 Diplomat, ABIM, subspecialty Hematology
2010 Kentucky Medical License (#43332)
PROFESSIONAL MEMBERSHIPS AND ACTIVITES
1998 Member, Kentucky Medical Association
1998 Member, American Medical Association
1999 Member, American College of Physicians
1999 President, Kentucky Medical Association Medical School Section, University of Louisville
2002-2010 Member, Massachusetts Medical Association
2003-2005 Resident Representative Massachusetts Council of Associates, American College of Physicians,
2005- Member, American Society of Clinical Oncology, member
2005- Member, American Society of Hematology
2006- 2009 Member, Clinical Practice Committee, American Society of Clinical Oncology
2010- Governing Council, American College of Physicians, Kentucky Chapter
2010- Nominating Committee, Greater Louisville Medical Society, Nominating Committee
2011- Member, Health Disparity Advisory Group (HDAG), American Society of Clinical Oncology
2011- Member, HDAG Quality subcommittee, American Society of Clinical Oncology
2011- Member, HDAG Public Policy subcommittee, American Society of Clinical Oncology
2011- Fellow, American College of Physicians
2013- Member, ASCO Health Disparities Quality Work Group
2014- Ad Hoc Reviewer, Journal of Oncology Practice
HONORS AND AWARDS
1994 Phi Eta Sigma Honor Society, Duke University, Durham, NC
1997 - 1998 Dean’s List, Duke University, Durham, NC
Elizabeth Riley, M.D., FACP 7/25/14
Page 3 of 19
3
1999 Finalist, Research! Louisville. University of Louisville. Louisville, KY: “Influence of Estrogen
Mimics on ERE Recognition by Human Estrogen Receptor- alpha.”
2000 Honorable Mention, Poster Session. Kentucky Medical Association Annual Meeting, Scientific
Exhibition. Louisville, KY: “Influence of Estrogen Mimics on ERE-Recognition by Human
Estrogen Receptor- alpha. “
2000 Walser Prize Runner-up, Poster Session. Clinical Ligand Assay Society Annual Meeting. Boston,
MA: “Influence of Estrogen Mimics on ERE Recognition by Human Estrogen Receptor- alpha.”
2011 Elected Fellow, American College of Physicians
2013 Selected as Focus Louisville September 2013 class
2014 Selected as Leadership Louisville “100 Wise Women”
2014 Selected as Louisville Business First “40 under 40”
COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES
Beth Israel Deaconess Medical Center/ Harvard Medical School
2003-2005 Fellow Member, Beth Israel Deaconess Cancer Committee
2006-2007 Chief Resident, Department Internal Medicine, Boston, MA
James Graham Brown Cancer Center (JGBCC)/University of Louisville:
2010- Member, University of Louisville Hospital Cancer Committee
2010 - Member, Medical Oncology Operational Leadership Group
2010- Reviewer, JGBCC Clinical Scientific Research Committee
2010- Steering Committee, National Accreditation Program of Breast Centers (NAPBC)
Accreditation
2010 Member, Pharmacy and Technology (P&T) Committee, James G. Brown Cancer Center
2011- Board Member, University Medical Associates
2011-2012 Chair, Psychosocial Distress Subcommittee, UofL Hospital Cancer Committee
2011-2013 Assistant Program Director, Brown Cancer Center Hematology/Oncology Fellowship
2011- Co-Director, Brown Cancer Center Mobile Mammography Research Group
2012- Member, Fellowship Competency Committee
2013 Member, University of Louisville School of Medicine Strategic Planning for Clinical
Enterprise Committee
2013 Founder and Chair, Brown Cancer Center Quality Committee
2013 Member, Brown Cancer Center Program Leadership Committee
2013 Judge, James G. Brown Cancer Center (JGBCC) 11th Annual Retreat Poster Competition 2013 Associate Division Director, Division of Hematology/ Oncology
2013 Director, Breast Cancer Multidisciplinary Clinic
2013 Chair, National Accreditation Program of Breast Cancers (NAPBC) Accreditation
Steering Committee
EDUCATIONAL ACTIVITES
2006-2007 Chief Resident, Internal Medicine, Beth Israel Deaconess Medical Center/Harvard
Medical School, Boston, MA
2010- 2012 Co- Author, Harvard Medical School Online CME Course “Anemia,”
(Mentor: Reed Drews M.D.)
Authored an online case based tutorial on the diagnosis and management of anemia for
Harvard Medical School’s online CME course.
Elizabeth Riley, M.D., FACP 7/25/14
Page 4 of 19
4
2010-2013 Subspecialty Education Coordinator, Hematology/Oncology for Internal Medicine
Residency Program, University of Louisville
Created and managed the UofL Internal Medicine Residency Educational Curriculum
including both inpatient and outpatient activities, as well as didactic topics
2011-2013 Assistant Program Director, Brown Cancer Center Hematology/Oncology Fellowship,
University of Louisville
Oversight and mentorship of 9 medical oncology/hematology fellows
2012-2013 Educational Curriculum Coordinator, BCC Hematology/Oncology Fellowship
Program, University of Louisville
Completely revised and updated the educational curriculum of the UofL hematology and
medical oncology fellowship program
Recurring Teaching Conferences/ Beth Israel Deaconess Medical Center/ Harvard Medical School
2005- Lecturer, Tumor Board
One hour long lectures given to 20 hematology-oncology and pathology faculty
members, fellows, residents and students. Topics included but not limited to:
Pharmacogenetics, Fertility Preservation in Cancer patients, Her 2 Neu Positive Breast
Cancer and Racial and Ethnic Disparities in Cancer.
2006-2009 Lecturer, Lymphoma Conference
2006-2007 Lecturer and Moderator, Medical Morbidity and Mortality Conferences
Presented summary of the hospital course of patients who sustained morbidity or
mortality during an inpatient hospitalization. Invited expert faculty discussants and
moderated the one-hour discussion held in front of 80-120 faculty, fellows, residents, and
medical students. One conference per month.
2006-2007 Lecturer and Moderator, Intern and Resident Reports
Prepared case-based reviews of core internal medicine topics for groups of 10-30 medical
residents and 20-40 medical interns and medical students. 1-2 reports were given each
week.
2006-2007 Moderator, Internal Medicine Teaching Attending
Led daily, hour-long educational sessions in various formats (e.g. case-based
presentations, lectures on core internal medicine topics) for groups of internal medicine
residents and medical students regarding the evaluation, diagnosis, and management of
patients admitted to the general internal medicine service. Reviewed written medical
student histories and physicals and observed medical student physical
examinations. Served in this role for three months during the academic year.
30 minute lectures given to 20 hematology-oncology and pathology faculty members,
fellows, residents and students. Topics included but not limited to: Primary Mediastinal
Lymphoma and Rituximab in TTP.
Recurring Teaching Conferences/ Brown Cancer Center Fellowship Conferences
2011 – 2013 Creator and moderator, New Patient Conference
Weekly case based discussions regarding new hematologic and oncologic patients with
fellows and invited expert faculty.
Elizabeth Riley, M.D., FACP 7/25/14
Page 5 of 19
5
2012 – 2013 Creator and moderator, Oncology Plus Conference
Quarterly panel discussions regarding common non-traditional topics regarding oncology
care such as quality, health care disparities, end of life coping and discussion and trainee /
professional burn out.
2012 – current Director, James G. Brown Cancer Center Grand Rounds
Oversee and organize speakers in shared radiation oncology, medical oncology and
hematology weekly conference
Invited Lectureships/ University of Louisville
2010 “Fertility Preservation in the Cancer Patient,” Multimodality Conference
2010 “BRCA 1 and 2 mutations,” Biochemistry lecture and panel discussion
2010 “Biology of Breast Cancer” UofL, Medical Oncology Core Curriculum
2010 “Adjuvant Endocrine therapy”” UofL Medical Oncology, Core Curriculum
2010- Hematology/Oncology Faculty Discussant Internal Medicine Noon Report
2011 “The Mammography Controversy: An Oncologist’s Perspective” UofL OB/GYN
Grand Rounds
2012 “Parp Inhibitors in Breast Cancer” Medical Oncology Journal Club
2011 “Thrombophilia 101” UofL Internal Medicine Residency Didactics
2011 “Breast Cancer” Brown Cancer Center Summer Internship Lecture Series
2011 “Initial Therapy for Advanced Stage Hodgkins Lymphoma” Hematology Conference
“Breast Cancer 101” UofL Internal Medicine Residency Didactics
2012 “Breast Cancer Clinical Overview” UofL Cancer biology graduate course
2012 “Overdiagnosis in Breast Cancer” UofL Department of Medicine Grand Rounds
2012 “Breast Cancer Overview” UofL Medical Oncology fellowship Core Curriculum
2013 “Rethinking DCIS” Brown Cancer Center Grand Rounds
2013 “Breast Cancer Biology” UofL Cancer Biology Course
2013 “Breast Cancer for the Internist” UofL Internal Medicine Residency Didactics
2013 “Breast Cancer” UofL Surgical Oncology Fellow Didactics
2013 “Multidisciplinary Cancer Care” UofL School of Medicine 4th Year Class
2014 “Breast Cancer 101” UofL Internal Medicine Residency Didactics
2014 “Breast Cancer Biology and Future Research Directions” NCI Summer Scholar Lecture
Series
Invited Lectureships/ Regional
2011 “Breast Cancer Update 2011” Owensboro Oncology Conference, Owensboro, KY
2011 “The Mammography Controversy: An Oncologist’s Perspective” Annual Meeting
Kentucky America College of Physicians, Louisville, KY
2012 “Think Pink!” Kentucky Cancer Program, Shepherdsville, KY
2013 “Breast Cancer Treatment and Decisions: 5 Questions to Ask Your Doctor” Women’s
Conference, Bowling Green, KY
2013 “Breast Cancer Risk” Louisville Junior League, Louisville, KY
Clinical and/ or Research Mentorship
Medical Students
2012-2013 Andrew O’Brien, University of Louisville
Residents
2012 Tarsheen Sethi, MD, Internal Medicine, University of Louisville
Elizabeth Riley, M.D., FACP 7/25/14
Page 6 of 19
6
2012- current Laura Barkley, MD, Radiology, University of Louisville
NCI Summer Scholar Mentees
2014- current Sarah Mudra, Wheaton, Chicago IL
Hematology/Oncology Fellows
2012 Blakely Kute, MD University of Louisville
2012- current Mounika Mandadi, MD, University of Louisville
2013- current Tezo Karedan, MD, University of Louisville
CLINICAL ACTIVITES
2009- present Multidisciplinary Outpatient Hematology/Oncology Clinic
Clinical Service: 2 full days per week (Average 50 patients/week, 5 new patients/week) I see approximately 2000 patients a year and approximately 200 new breast cancer
patients each year. My primary clinical focus is the treatment of these women (and some
men) in all stages of breast cancer and survivorship. Additional areas of focus include
hematology (benign and malignant) and breast cancer risk reduction.
Sites: James G. Brown Cancer Center (JGBCC)
2009- current Hematology/Oncology Inpatient Service
Clinical Service: 3 months per year (average 20 patient/day)
Sites: University of Louisville Hospital (ULH,) Norton Downtown Hospital, Jewish
Downtown Hospital and the Louisville VA Hospital
2009- current Clinical Trial Principal Investigator
Clinical Service: PI on average of 6 open trials in breast cancer and hematology, sub I or
co-investigator on additional 15-20 open studies
Sites: ULH, JGBCC
2013- current Associate Division Director, Division of Hematology/Oncology
Clinical Service: Clinical director of medical oncology/ hematology clinical faculty
practice within the Multidisciplinary Clinics at the JGBCC. Revised triage practices and
hematology referral system at the JGBCC (latter in development) and restructured
consult service at Jewish Hospital Downtown.
Sites: ULH, JGBCC, Norton Downtown Hospital, Jewish Hospital Downtown.
2013- current Director, Breast Cancer Multidisciplinary Clinic, JGBCC
Clinical Service: Director of Kentucky’s first accredited breast program by the National
Accreditation Program of Breast Centers (NAPBC.) Responsible for maintenance of
accreditation and oversight of the multidisciplinary clinic which includes medical
Elizabeth Riley, M.D., FACP 7/25/14
Page 7 of 19
7
oncology, radiation oncology, surgical oncology, genetics, mammographic radiology, and
pathology.
Sites: JGBCC
RESEARCH FUNDING/ ACTIVITES
Past Support: Mentored Research
1. Resident Work Hours Implications on Error
Evaluated resident and attending perspectives on the ACGME’s 80 hour work week regulations
and resident error
Mentor: Anjala Tess M.D. Department of Medicine, Beth BIDMC, Boston, MA
2005
2. Comparison of local and central renal cell pathology interpretations
Evaluated concordance of local pathology interpretation (LR) with central pathology review (CR)
in primary tumor specimens from patients with renal cancer (RCC).
Mentor: Michael B. Atkins, M.D., Director Biologics Program, Department of Oncology, BIDMC,
Boston, MA
2004-2005
3. Quantitative Analysis of Synthetic and Phytoestrogens on ER-alpha Activity
Laboratory based research aimed at developing a method to quantitatively analyze estrogen
mimics’ influence on recombinant human estrogen receptor alpha activity.
Mentor: James L.Wittliff, Ph.D., Director Hormone Receptor Laboratory, James Brown Cancer
Center, University of Louisville, Louisville, KY
1999
Current Support: Investigator Initiated Research
1. Mobile Mammography Project 1: The impact of mobile mammography on trends and disparities in
the diagnosis of breast cancer at a comprehensive cancer center in an underserved state.
Analysis of demographic, racial and ethnic trends in mobile mammography utilization in Jefferson
County, KY
Role Co- PI
Period of Support 2011 - ongoing
Award Intramural funding
2. Survey of the Quality of Life of Patients with Breast Cancer Treated with Chemotherapy
in the Neoadjuvant vs. Adjuvant Setting
Elizabeth Riley, M.D., FACP 7/25/14
Page 8 of 19
8
Comparison of health related quality of life between breast cancer chemotherapy patients treated
before vs. after surgical treatment.
Role PI
Period of Support 2014-2016
Award $39,858.00
3. Estimating the Adherence of Oral Anti-estrogens with a Bubble Pack
Investigator initiated Phase II Feasibility study investigating altering breast cancer therapy pill
packaging in an effort to improve compliance
Role PI
Period of Support 2012 to current or 120 patients
Award $86,980.00
4. Mobile Mammography Project 2: Development of a clinical database of women diagnosed through
the Mobile Mammography Van of the Kentucky Cancer Program
Estimation of risk factors and biological features of breast cancer diagnosed through the mobile
mammography van in Jefferson County, KY
Role Co- Director Research Group, Project PI
Period of Support 2014-
Award Intramural Funding
Under development/Pending Support: Investigator Initiated Research
1. Mobile Mammography at the JGBCC: Reviewing and Implementing Hispanic Outreach
Evaluation of mobile mammography by the currently most vulnerable ethnic group for repeat van
utilization in Jefferson County, KY
Role Co- Investigator
Award pending
Past Support: Clinical Research
1. NSABP Cooperative Group Trial Support
Title: Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast
Cancer.
Role: University of Louisville site Principal Investigator (from 2009-20012)
Period of Support: 1999-2012
Total Award: $160,738.29
Direct Amount $127,570.07
Elizabeth Riley, M.D., FACP 7/25/14
Page 9 of 19
9
2. Novartis Pharmaceuticals Trial Support
Title: A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in
combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-
expressing locally advanced or metastatic breast cancer
Role: Sub investigator (PI Jain, D)
Period of support 2010-2011
Total award $7,834.00
Direct amount $6,217.46
3. Genetech Pharmaceutical Trial Support
Title MARIANNE A randomized, 3 arm, multicenter, phase III study to evaluate the efficacy
and the safety of T-DM1 combined with Pertuzumab or T-DM1 combined with
Pertuzumab-Placebo, versus the combination of Herceptin plus taxane, as 1st line
treatment in HER2 positive progressive or recurrent locally advanced or metastatic
breast cancer
Role Sub investigator (PI Jain, D)
Period of support 2010-2011
Total award $12,854.00
Direct amount $10,201.59
4. ISIS Trial Support
Title A Phase 1b/2 Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an
eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer
Role Sub investigator (PI Kloecker, G)
Period of support 2011 -2014
Total award $41,312.00
Direct amount $32,787.30
5. SuperGen Trial Support
Title A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination with
Platinum- Etoposide Chemotherapy in Small Cell Lung Cancer Subjects who have not
Responded to Standard Treatment or Relapsed After Standard Treatment
Role Sub Investigator (PI Kloecker, G)
Period of Support 2011-2013
Total Award $42,516.00
Direct Amount $33,742.86
Current Support: Clinical Research
Elizabeth Riley, M.D., FACP 7/25/14
Page 10 of 19
10
1. NSABP Cooperative Group Trial Support
Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy
Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of
Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to
Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk
Node-Negative HER2-Low Invasive Breast Cancer
Role: University of Louisville site Principal Investigator
Period of Support: 2011- ongoing
Total Award $17,567.25
Direct Amount $13,942.26
2. Galena Trial Support
Title: PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer
with Low to Intermediate HER2 Expression with NeuVax(tm) Treatment
Role: University of Louisville site Principal Investigator
Period of Support: 2012- ongoing
Total Award $16,802.02
Direct Amount $13,335.08
3. Genetech Pharmaceutical Trial Support
Title An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the
Efficacy and Safety of Bendamustine Compared with Bendamustine + Ro5072759
(Ga101) in Patients with Rituximab-Refractory, Indolent Non-Hodgkin’s
Lymphoma
Role University of Louisville site Principal Investigator
Period of Support 2013- ongoing
Total Award $8,221.26
Direct Amount $6,524.81
4. ECOG Cooperative Group Trial Support
Title E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the
Intact Primary Tumor in Patients with Metastatic Breast Cancer
Role University of Louisville site Principal Investigator
Period of Support 2013- ongoing
Total Award n/a
5. NSABP Cooperative Group Support
Title NSABP B-38 06.0075 - A Phase III, Adjuvant Trial Comparing Three Chemotherapy
Regimens in Women with Node Positive Breast Cancer: Docetaxel/ Doxorubicin/
Cyclophosphamide (TAC); Dose Dense (DD) Doxorubicin/Cyclophosphamide followed by
DD Paclitaxel (DD AC —> P); DD AC followed by DD Paclitaxel Plus Gemcitabine (DD
AC —> PG) Role Sub Investigator (PI Jain, D)
Elizabeth Riley, M.D., FACP 7/25/14
Page 11 of 19
11
Period of Support 2006-
Total Award $8000
Direct Amount $6349.21
6. Cooperative Group Support
Title PACCT-1 06.0362 - Program for the Assessment of Clinical Cancer Tests: Trial Assigning
Individualized Options for Treatment: the TailorRx Trial
Role: Sub Investigator (PI Jain, D)
Period of Support: 2006-
Total Award $90,500.00
Direct Amount $71,825.40
7. NSABP Cooperative Group Support
Title B-42 Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared
to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an
Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free
Survival in Postmenopausal Women with Hormonal Receptor Positive Breast Cancer
Role: Sub Investigator (PI Jain, D)
Period of Support: 2006-
Total Award n/a
Direct Amount n/a
8. NSABP Cooperative Group Support
Title B-40 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and
Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of
Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or
without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of
High Likelihood for pCR with Each of the Regimens
Role Sub Investigator (PI Jain, D)
Period of Support 2007-
Total Award $27,744.00
Direct Amount $22,019.05
9. ACOSOG Cooperative Group Trial Support
Title Z 1041: A Randomized Phase III trial comparing Neoadjuvant Regimen of FEC-75 followed
by Paclitaxel Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab
Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast
Cancer
Role Sub Investigator (PI Jain, D)
Period of Support 2009-
Total Award $15,250.00
Direct Amount $12,103.17
Elizabeth Riley, M.D., FACP 7/25/14
Page 12 of 19
12
10. Cooperative Group Trial Support
Title ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study; A
Randomized, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib,
Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2
Positive Primary Breast Cancer
Role Sub Investigator (PI Jain, D)
Period of Support 2009-
Total Award $25,600.00
Direct Amount $20,317.36
11. RTOG Cooperative Group Trial Support Title RTOG-0413 NSABP B-39 09.0287 - (prev. 06.0217) A randomized Phase III study of
Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for
Women with stage 0, I, or II Breast Cancer
Role Sub Investigator (PI Woo, S)
Period of Support 2009-
Total Award $6,550.00
Direct Amount $5,198.41
12. Novartis Pharmaceutical Clinical Trial Support
Title A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with
Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive,
Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or
Anastrozole.
Role Sub Investigator (PI Jain, D)
Period of Support 2010-
Total Award $24,901.00
Direct Amount $19,762.70
13. Imclone Clinical Trial Support
Title An Open-label, Multicenter, Randomized, Phase 2 Study of a recombinant Human Anti-
VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based
Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of
Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)
Role Sub Investigator (PI Kloecker, G)
Period of Support 2010-
Total Award $43,631
Direct Amount $34,627.78
14. Eisai Pharmaceutical Clinical Trial Support
Elizabeth Riley, M.D., FACP 7/25/14
Page 13 of 19
13
Title ELEVATE- A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy
and Safety of Eribulin with Treatment of Physician’s Choice in Subjects with Advanced Non-
Small Cell Lung Cancer.
Role: Sub Investigator (PI Kloecker, G)
Period of Support: 2012-
Total Award $54,538.00
Direct Amount $43,284.13
15. Pfizer Pharmaceutical Clinical Trial Support
Title ARCHER 1009 -A Randomized Double Blind Phase 3 Efficacy and Safety Study Of PF-
00299804(Dacomitinib) Versus Erlotinib for the Treatment Of Advanced Non Small Cell Lung
Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy
Role Sub Investigator (PI Kloecker, G)
Period of Support 2012-
Total Award $39,357.00
Direct Amount $31,235.71
16. Boehringer Pharmaceutical Clinical Trial Support
Title LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients
with advanced squamous cell carcinoma of the lung a second-line therapy following first-line
platinum-based chemotherapy
Role Sub Investigator (PI Kloecker, G)
Period of Support 2013-
Total Award $20,758.00
Direct Amount $16,474.60
17. NSABP Cooperative Group Clinical Trial Support
Title B-49 A Phase III clinical Trial Comparing the Combination of Docetaxel Plus
Cyclophosphamide to Anthracycline Based Chemotherapy Regimens for Women with Node
Positive or High Risk Node Negative, Her 2 Negative Breast Cancer
Role Sub Investigator (PI Jain, D)
Period of Support 2012-
Total Award $8,000.00
Direct Amount $6,349.21
18. Lilly Pharmaceutical Support
Title A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy
Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV
Squamous Non-Small Cell Lung Cancer (NSCLC)
Role Sub Investigator (PI Kloecker, G)
Period of Support 2013-
Total Award $16,973.00
Direct Amount $13,470.63
Elizabeth Riley, M.D., FACP 7/25/14
Page 14 of 19
14
19. James Graham Brown Cancer Center
Title Protocol for the Cancer Database and Specimen Repository (CDSR) at the James Graham
Brown Cancer Center (Previous Lung Repository <LDSR>)
Role Sub Investigator (PI Kloecker, G)
Period of Support 2008-
Total Award intramural
Direct Amount intramural
20. James Graham Brown Cancer Center
Title A Phase II Trial of Extended Interval Port Flushes
Role Sub Investigator (PI Kloecker, G)
Period of Support 2009-
Total Award intramural
Direct Amount intramural
21. SWOG Cooperative Group Clinical Trial Support
Title S1007 - A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/-
Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-
Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Role Sub Investigator (PI Jain, D)
Period of Support 2011-
Total Award $17,375.00
Direct Amount $13,789.68
22. Transgene Pharmaceutical Clinical Trial Support
Title A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line
therapy with or without TG4010 immunotherapy product in patients with stage IV non-small
cell lung cancer (NSCLC)
Role Sub Investigator (PI Kloecker, G)
Period of Support 2013-
Total Award $8,222.00
Direct Amount $6,525.40
23. Amgen Pharmaceutical Clinical Trial Support
Title Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen
or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and
Pegfilgrastim
Role Sub Investigator (PI Jain, D)
Period of Support 2013-
Total Award n/a
Direct Amount n/a
Elizabeth Riley, M.D., FACP 7/25/14
Page 15 of 19
15
24. Pfizer Pharmaceutical Clinical Trial Support
Title A Randomized, Multicenter, Double-Blind Phase 3 Study of Pd-0332991 (Oral Cdk 4/6
Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal
Women with Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-
Cancer Treatment for Advanced Disease
Role Sub Investigator (PI Jain, D)
Period of Support 2013
Total Award $8473.00
Direct Amount $6724.60
25. James Graham Brown Cancer Center
Title PACE 13.0338 - PACE of Breast Cancer (Predicting Adverse Cardiac Events of BC)
Role Sub Investigator (PI Lenneman, C)
Period of Support 2014
Total Award intramural
Direct Amount intramural
26. Amgen Pharmaceutical Clinical Trial Support
Title A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and
Efficacy of Darbepoetin Alfa Administered at 500 μg Once-Every-3-Weeks in Anemic Subjects
With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Role Sub Investigator (PI Kloecker, G)
Period of Support 2014-
Total Award n/a
Direct Amount n/a
27. ACT Advanced Cancer Therapeutics Clinical Trial Support
Title A Phase 1, Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients
with Advanced Solid Malignancies
Role Sub Investigator (PI Redman, R)
Period of Support 2014
Total Award n/a
Direct Amount n/a
PATENTS
None
EDITORIAL WORK
Elizabeth Riley, M.D., FACP 7/25/14
Page 16 of 19
16
2014 Ad Hoc Journal of Oncology Practice (JOP)
ABSTRACTS AND PRESENTATIONS
ORAL PRESENTATIONS
1. Mizuguchi S, Barkley L, Roland L, Rai SN, Pan J, Riley EC Mobile Mammography
Utilization Trends and Disparities Over a Decade at a Comprehensive Urban Cancer
Center. Oral presentation, Radiological Society of North America December 2013.
POSTERS
1. Carloss EA, Vago B, & Wittliff JL. Influence of Estrogen Mimics on ERE-
Recognition by Human Estrogen Receptor-a. 2000 Clinical Ligand Assay Society
Annual Meeting. Boston, MA.
2. Carloss E, Regan M, Upton M, Youmans A, McDermott D, Polivy A, , Atkins A.
Concordance of local pathology interpretation (LR) with central pathology review
(CR) in primary tumor specimens from patients with renal cancer (RCC). Poster
Session: Genitourinary Cancer, 2004 ASCO Annual Meeting.
3. Dragun AE, Pan J, Riley E, Kruse B, Wilson M, Rai S, Jain D. Increasing use of
mastectomy with immediate reconstruction and contralateral prophylactic
mastectomy in breast conservation candidates: A 14-year report from a
comprehensive cancer center. Poster Session Breast Cancer - Triple-
negative/Cytotoxics/Local Therapy. 2011 ASCO Annual Meeting. J Clin Oncol 29:
2011 (suppl; abstr 1104) Presenter
4. Barry PN, Riley EC, Pan J, Crew JB, Le K, Jain D, Kruse B, Quillo AR, Rai S,
Dragun AE. Delay of Adjuvant Chemotherapy after Elective Mastectomy and
Immediate Reconstruction in Breast Conservation Candidates: A Matched – Pair
Analysis. Poster Session. CTRC-AACR San Antonio Breast Cancer Symposium
2011. Cancer Res; 71 (24 suppl.) Dec 2011
5. Milam MR, Cummings S; Wilcox L; Riley EC; Soliman PT; Myers JA . Risk
Factors for Uterine Cancer in Breast Cancer Survivors: An Army of Women Study.
61st Annual Clinical Meeting The American College of Obstetricians and
Gynecologists. New Orleans, LA. May 2013.
6. Riley EC, Roland LC, Barkley L, Mandadi M, Rai SN, Pan J and Mizuguchi SG
Insurance Status to predict repeat Mobile mammography Utilization: 10 year
analysis of a Comprehensive Urban Cancer Center Poster Session CTRC- AACR
San Antonio Breast Cancer Symposium December 2013.
7. Riley EC, Jain D, Kantardzic B, Wu X, Rai, SN Demographic Trends in Clinical
Trial Withdrawal Rate within the Bubble Study. Poster Session CTRC- AACR San
Antonio Breast Cancer Symposium December 2013
Elizabeth Riley, M.D., FACP 7/25/14
Page 17 of 19
17
8. Riley EC, Roland LC, Barkley, Rai SN, Pan J and Mizuguchi SG Impact of
Location to Repeat Mobile Mammography Utilization Trends: 10 year analysis of a
Comprehensive Urban Cancer Center. Poster Session ASCO Annual Meeting 2014.
9. Riley EC, Dragun A, McMasters K, Scoggins C, Quillo A, Rai S, Wu X, Jain D
Compliance with oral antiestrogens utilizing a bubble pack. Poster Session ASCO
Breast Symposium Sept 2014.
10. Riley EC, Roland LC, Barkley, Rai SN, Pan J and Mizuguchi SG Uninsured
utilization of the mobile mammography: 10-year analysis. Poster Session ASCO
Breast Symposium Sept 2014.
11. Dragun A, Riley E, Quillo A, Barry P, Hunter A, Rajeur A, Roberts T, Rai S, Pan J,
Jain D, Scoggins C, McMasters K A phase II trial of once-weekly hypofractionated
breast irradiation (WHBI): Interim analysis of cosmetic outcome and quality of life.
Poster Session ASCO Breast Symposium Sept 2014.
Submitted Abstracts/Pending
1. Riley EC, Roland LC, Barkley, Rai SN, Pan J and Mizuguchi SG Multivariable Analysis of Repeat
Utilization of Mobile Mammography Units: 10 year analysis of a Comprehensive Cancer Center
Submitted June 2014 to San Antonio Breast Cancer Symposium 2014
2. Riley EC, Dragun A, McMasters K, Quillo A, Scoggins C , Wu X, Rai S, Jain, D. Demographic trends
in clinical trial withdrawal rate within the bubble study: Updated analysis. Submitted June 2014 to
ASCO Quality Symposium 2014.
PUBLICATIONS
PEER REVIEWED
1. Carloss H, Huang B, Cohen A, Carloss E, Wyatt S, Tucker T. The Impact of Number of Lymph
Nodes Removed on 5 Year Survival in Stage II Colon and Rectal Cancer. J. KY Med Assoc. 2004
Aug; 102(8):345-7.
2. Sharma V, Brannon M, Carloss E. Refractoriness to Oral Iron Replacement in Patients with Iron
Deficient Anemia Taking Omeprazole. South Med J. 2004 Sep;97(9): 887-9.
3. Huang, B, Carloss H, Wyatt, S, Riley E. Hormone Replacement Therapy and Survival of Lung cancer
in Postmenopausal Women in a Rural Population. Cancer 2009; 115(18): 4167-4175.
4. Riley, E, Drews, R " Anemia" Harvard University Online CME Curriculum Program 2010
http://cmeonline.med.harvard.edu/course_descriptions.asp?Course_id=114&group_name=Medicine
5. Riley, E, Carloss, H Dramatic Response to Panitumumab and Bevacizumab in Metastatic Gallbladder
Carcinoma The Oncologist 2011; 16: e1-e2; doi:10.1634/theoncologist.2008-0196
http://theoncologist.alphamedpress.org/cgi/content/full/16/5/e1
Elizabeth Riley, M.D., FACP 7/25/14
Page 18 of 19
18
6. Riley E, Moy, B Ethical Challenges: Caring for the Underinsured Geographically Disadvantaged
Patient. J Oncol Prac 8:215-218, 2012
7. Dragun, A, Quillo, A, Riley, E et al, A Phase 2 Trial of Once-Weekly Hypofractionated Breast
Irradiation: First Report of Acute Toxicity, Feasibility and Patient Satisfaction Int J Radiat Oncol Biol
Phys. 2013 Mar 1;85(3):e123-8. doi: 10.1016/j.ijrobp.2012.10.021. Epub 2012 Nov 27.
8. Dragun AE, Pan J, Riley EC, Kruse B, Wilson MR, Rai S, Jain D. Increasing the use of elective
mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14 -
year report from a comprehensive cancer center. Am J Clin Oncol. 2013 Aug;36(4):375-80. doi:
10.1097/COC.0b013e318248da47
9. Barry PN, Riley EC, Pan J, Crew JB, Lee K, Jain D, Kruse B, Quillo AR, Rai S, Dragun AE. Delay of
Adjuvant Chemotherapy After Elective Mastectomy and immediate reconstruction in breast-
conservation candidates: a matched-pair analysis. Am J Clin Oncol. 2013 Mar 4. [Epub ahead of print]
PubMed PMID: 23466579
10. Boone S, Baumgartner K, Baumgartner R, Cooner A, Pinkston C, Rai S, Riley E, Hines L, Giuliano A,
John E, Stern M, Torres-Mejia G, Wolff R, Slattery M. Associates between CYP19A1
polymorphisms, Native American Ancestry, and breast cancer risk and mortality: the Breast Cancer
Health Disparities Study. Cancer Causes and Control, accepted July 2014 pending publication.
Under Review/Submitted
11. Mizuguchi S, Barkley L, Rai S, Pan J, Roland L, Crawford S, Riley, E Mobile Mammography and
Race: Utilization Trends Over a Decade at a Comprehensive Urban Cancer Center. Under Review
JOP submitted March 2014
12. Torres D, Myers A, Cummings S, Wilcox L, Riley E, Soliman P, Milam, M Risk Factors for the
Development of Uterine Cancer in Breast Cancer Survivors: An Army of Women Study. Submitted
Annuals of Oncology, April 2014.
NON PEER REVIEWED
Book Chapters
1. Sethi, T, Riley, E “Antiphospholipid Antibody Syndrome” 5 Minute Clinical Consult, 2014
Edition
2. Sethi, T, Riley, E “Antiphospholipid Antibody Syndrome” 5 Minute Clinical Consult, 2015
Edition